Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Glaukos Corporation

In a report released today, Michael Sarcone from Jefferies maintained a Buy rating on Glaukos, with a price target of $130.00. Sarcone covers the H...

Jefferies Keeps Their Buy Rating on Glaukos (GKOS)

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on Glaukos today and set a price target of $115.00. Stephan covers the Healthcare se...

Stifel Nicolaus Reaffirms Their Buy Rating on Glaukos (GKOS)

Piper Sandler analyst Adam Maeder maintained a Buy rating on Glaukos today and set a price target of $165.00. Maeder covers the Healthcare sector, ...

Piper Sandler Remains a Buy on Glaukos (GKOS)

Glaukos Corp. (($GKOS)) has held its Q3 earnings call. Read on for the main highlights of the call. Glaukos Corp. recently held its earnings call, ...

Glaukos Corp. Reports Record Sales and FDA Approval

In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Glaukos, with a price target of $165.00. The company’s shares...

Piper Sandler Keeps Their Buy Rating on Glaukos (GKOS)

Glaukos Corp. ( ($GKOS) ) has released its Q3 earnings. Here is a breakdown of the information Glaukos Corp. presented to its investors. Glaukos Co...

Glaukos Corp. Reports Record Q3 Sales Growth

Glaukos ( ($GKOS) ) has provided an announcement. In its third quarter of 2025, Glaukos reported record net sales of $133.5 million, marking a 38% ...

Current Quarter	$-0.21	Next Quarter	$-0.15
Current Year	$-0.85	Next Year	$-0.21
QoQ Growth	+28.6%	YoY Growth	+75.3%
3Y EPS CAGR	-37.3%	Target Price	$120.50
Consensus	Buy	Upside	+21.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GKOS	$99.62	+4.64%	1.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GKOS	$99.62	+4.6%	1.29M
3
4
5
6

GKOS

GKOS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Glaukos Corporation Data in Excel

Get Glaukos Corporation Data in Excel